Compare DAVA & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAVA | VYGR |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.4M | 227.2M |
| IPO Year | 2015 | 2015 |
| Metric | DAVA | VYGR |
|---|---|---|
| Price | $4.16 | $3.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | $13.50 | ★ $16.50 |
| AVG Volume (30 Days) | 216.5K | ★ 488.9K |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,135,000.00 |
| Revenue This Year | N/A | $34.04 |
| Revenue Next Year | $4.07 | $7.92 |
| P/E Ratio | $20.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.98 | $2.65 |
| 52 Week High | $20.80 | $5.55 |
| Indicator | DAVA | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 47.72 |
| Support Level | N/A | $3.72 |
| Resistance Level | $7.04 | $4.31 |
| Average True Range (ATR) | 0.22 | 0.16 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 17.43 | 31.91 |
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.